Fig. 4

Early depletion of Tregs modulates the phenotype of plaque-associated reactive astrocytes. A,E Representative images of astrocytes (GFAP, green) and their expression of the A1-like astrocytic marker C3 (blue) associated to amyloid deposits (Aβ, white) in the cerebral cortex of mice treated with either a control or anti-CD25 antibody (A) or with either PBS or IL-2 (E). B, F Quantification of GFAP area colocalized with C3 in close vicinity to amyloid deposits of different size ranges in the cerebral cortex of mice treated with either a control or anti-CD25 antibody (B) or with either PBS or IL-2 (F). C,G Representative images of astrocytes (GFAP, green) and their expression of the A2-like astrocytic marker Cox2 (blue) associated to amyloid deposits (Aβ, white) in the cerebral cortex of mice treated with either a control or anti-CD25 antibody (C) or with either PBS or IL-2 (G). D,H Quantification of GFAP area colocalized with Cox2 in close vicinity to amyloid deposits of different size ranges in the cerebral cortex of mice treated with either a control or anti-CD25 antibody (D) or with either PBS or IL-2 (H). Results are represented according to the size of amyloid deposits. Unrecruited astrocytes are referenced as Ø. Mean +/− SEM (n > 10 amyloid deposits from 4–6 mice/ group). Mann–Whitney test: *P < 0.05; **P < 0.01; ***P < 0.001